TY - JOUR
T1 - New dimensions in the pharmacologic treatment of schizophrenia and related psychoses
AU - Buckley, Peter F.
PY - 1997/5
Y1 - 1997/5
N2 - During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.
AB - During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.
UR - http://www.scopus.com/inward/record.url?scp=0030946974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030946974&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1997.tb04314.x
DO - 10.1002/j.1552-4604.1997.tb04314.x
M3 - Review article
C2 - 9156369
AN - SCOPUS:0030946974
SN - 0091-2700
VL - 37
SP - 363
EP - 378
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
IS - 5
ER -